What's the latest news in Dry Eye?

This article investigates the efficacy of topical ivermectin 1.0% cream in treating ocular demodicosis, a condition caused by the proliferation of Demodex mites on the ocular surface.

Tarsus, a leading pharmaceutical company, has just received FDA approval for Xdemvy, the revolutionary topical therapeutic designed to combat Demodex blepharitis. Formerly known as TP-03, is a novel prescription eye...

Xiidra (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.

Vevye had the development name CyclASol during study and it is the first and only water-free topical cyclosporine ophthalmic solution indicated for the treatment of dry eye disease. 

Cequa, a prescription eye drop that helps to treat chronic dry eye disease, is now available on the PBS for adults living with moderate to severe dry eye disease.

A recent study (2023) evaluated the effects of physical activity/exercise on tear film characteristics and dry eye associated symptoms:

The World Health Organization (WHO) has identified a new COVID-19 subvariant, called Arcturus. One of the most common symptoms of Arcturus is pink eye (conjunctivitis).

In January and February 2023, several brands of eye drops were recalled due to contamination concerns. The recalls affected a total of four products:

Miebo (perfluorohexyloctane ophthalmic solution) is the first and only FDA-approved treatment that directly targets tear evaporation.